Introduction: The Notch pathway is involved in determining cell fate during development and postnatally in continuously renewing tissues, such as the endothelium, the epithelium, and in the stem cells pool. The dysregulation of the Notch pathway is one of the causes of limited response, or resistance, to available cancer treatments and novel therapeutic strategies based on Notch inhibition are being investigated in preclinical and clinical studies in oncology. A large body of evidence now shows that the dysregulation of the Notch pathway is also involved in the pathophysiology of cardiovascular diseases (CVDs). Areas covered: This review discusses the molecular mechanisms involving Notch which underlie heart failure, aortic valve calcification, and aortic aneurysm. Expert opinion: Despite the existence of preventive, pharmacological and surgical interventions approaches, CVDs are the first causes of mortality worldwide. The Notch pathway is becoming increasingly recognized as being involved in heart failure, aortic aneurysm and aortic valve calcification, which are among the most common global causes of mortality due to CVDs. As already shown in cancer, the dissection of the biological processes and molecular mechanisms involving Notch should pave the way for new strategies to prevent and cure these diseases.

Original languageEnglish
Pages (from-to)695-710
Number of pages16
JournalExpert Opinion on Therapeutic Targets
Volume23
Issue number8
Early online date14 Jul 2019
DOIs
StatePublished - 3 Aug 2019

    Research areas

  • aortic aneurysm, aortic valve calcification, cardiotoxicity, Dll4, endothelial dysfunction, heart failure, macrophages, Notch, Notch1, ARTERIOVENOUS-MALFORMATIONS, AORTIC-ANEURYSM, HEART-FAILURE, IMPROVES CARDIAC-FUNCTION, ENDOTHELIAL NOTCH1, SIGNALING PATHWAY, CLONAL HEMATOPOIESIS, MYOCARDIAL ISCHEMIA/REPERFUSION, PROMOTES VASCULAR MATURATION, PHASE-I

    Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Clinical Biochemistry
  • Pharmacology

ID: 49027904